We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 82.24%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
51
Ligand Pharmaceuticals
LGND
$5.71B
$7.86M 0.08%
117,638
– –
RARE icon
52
Ultragenyx Pharmaceutical
RARE
$2.55B
$7.84M 0.08%
123,894
– –
SAGE
53
DELISTED
Sage Therapeutics
SAGE
$7.18M 0.08%
224,048
+119,048
+113% +$4.19M
MGNX icon
54
MacroGenics
MGNX
$261M
$6.82M 0.07%
363,676
– –
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.77M 0.07%
495,908
– –
PRQR icon
56
ProQR Therapeutics
PRQR
$330M
$6.59M 0.07%
1,349,719
+361,420
+37% +$1.84M
CPRX
57
DELISTED
Catalyst Pharmaceutical
CPRX
$6.43M 0.07%
5,498,459
-2,777,171
-34% -$4.31M
DERM
58
DELISTED
Dermira, Inc.
DERM
$5.69M 0.06%
275,000
– –
AKTX
59
Akari Therapeutics
AKTX
$15.3M
$5.54M 0.06%
495
– –
IOVA icon
60
Iovance Biotherapeutics
IOVA
$3.76B
$5.42M 0.06%
1,066,285
-751,144
-41% -$4.11M
ECYT
61
DELISTED
Endocyte, Inc. Common Stock
ECYT
$5.26M 0.06%
1,695,865
– –
ARWR icon
62
Arrowhead Research
ARWR
$12.3B
$4.87M 0.05%
1,009,509
– –
NDRM
63
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.31M 0.05%
305,000
– –
NTRA icon
64
Natera
NTRA
$47.9B
$4.28M 0.05%
450,000
+200,000
+80% +$1.69M
VTAE
65
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$4.23M 0.04%
637,597
+450,000
+240% +$4.09M
RXDX
66
DELISTED
Ignyta, Inc.
RXDX
$3.87M 0.04%
571,000
– –
LOXO
67
DELISTED
Loxo Oncology, Inc
LOXO
$3.77M 0.04%
137,735
– –
TRVN
68
DELISTED
Trevena, Inc.
TRVN
$3.72M 0.04%
720
– –
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
$3.64M 0.04%
299,356
– –
AIMT
70
DELISTED
Aimmune Therapeutics
AIMT
$3.39M 0.04%
250,000
– –
GNMX
71
DELISTED
Aevi Genomic Medicine Inc
GNMX
$3.37M 0.04%
765,000
– –
MCRB icon
72
Seres Therapeutics
MCRB
$45.8M
$3.32M 0.04%
6,250
– –
CRIS icon
73
Curis
CRIS
$3.83M
$3.22M 0.03%
1,000
– –
NBRV
74
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.14M 0.03%
1,400
– –
JUNO
75
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.05M 0.03%
80,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2016 Portfolio in Review

As of Q1 2016, Julian Baker held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Julian Baker withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Julian Baker's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Julian Baker added most to Incyte in Q1 2016, an estimated $300M increase.
  • Julian Baker's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Julian Baker fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Julian Baker's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Julian Baker opened 5 new positions and closed 5 in Q1 2016.
  • Julian Baker's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.